Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 197

Sort by

Sort Order Select

Journal Articles

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Blood (2021) 137 (22): 3093–3104.

https://doi.org/10.1182/blood.2020007626

Published: 2021

Includes: Supplemental data

Journal Articles

New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis

Andreas Reiter, Tracy I. George, Jason Gotlib

Blood (2020) 135 (16): 1365–1376.

https://doi.org/10.1182/blood.2019000932

Published: 2020

Journal Articles

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Blood (2020) 135 (5): 371–380.

https://doi.org/10.1182/blood.2019002697

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo, Andrew H. Wei

Blood (2020) 135 (2): 85–96.

https://doi.org/10.1182/blood.2019001239

Published: 2020

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

Eunice S. Wang, MD, Elizabeth A. Griffiths, MD, Roland B. Walter, MD PhD MS, Martin S. Tallman, MD, Aaron D Goldberg, MD PhD, Boo Messahel, MD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 3829.

https://doi.org/10.1182/blood-2019-130536

Published: 2019

Journal Articles

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Samah Nassereddine, MD, Kimberley Doucette, MD MSc, Vanya Aggarwal, Richard Amdur, PhD, Imad A. Tabbara, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 2212.

https://doi.org/10.1182/blood-2019-124150

Published: 2019

Journal Articles

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Kwanza Price, MPH, Zhun Cao, PhD, Craig Lipkin, Scott Robinson, Deborah Ann Profant, PhD

Blood (2019) 134 (Supplement_1): 2213.

https://doi.org/10.1182/blood-2019-127075

Published: 2019

Journal Articles

Liposomal Daunorubicin/Cytarabine As a Bridge to Donor Lymphocyte Infusion or Allogeneic Stem Cell Transplantation for High-Risk Acute Myelogenous Leukemia

Daulath Singh, MD, Patrick Hagen, MD, Nasheed Hossain, MD, Scott E. Smith, MD PhD, Patrick J. Stiff, MD, Stephanie B. Tsai, MD MS

Blood (2019) 134 (Supplement_1): 5726.

https://doi.org/10.1182/blood-2019-129380

Published: 2019

Journal Articles

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

Blood (2019) 134 (Supplement_1): 4204.

https://doi.org/10.1182/blood-2019-126538

Published: 2019

Journal Articles

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Michael A Spinner, Alexey Aleshin, MD MBA, Marianne A Santaguida, PhD, Steven A Schaffert, PhD, Taher Abbasi, MS, MBA, Jeffrey N Sanders, A Scott Patterson, MA, Diane Heiser, PhD, James L Zehnder, Peter L Greenberg, MD

Blood (2019) 134 (Supplement_1): 4239.

https://doi.org/10.1182/blood-2019-129473

Published: 2019

Journal Articles

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Sabine Kayser, MD, Michelle A Elliott, MD, Marlise Luskin, MDMS, Andrew M. Brunner, MD, Michael Kramer, M.Sc., Zdenek Racil, MD, Zuzana Sustkova, MD, Petr Cetkovsky, MD MBA, PhD, Jan Novak, MD PhD, Friedrich Stoelzel, MD, Christian Thiede, MD, Carsten Müller-Tidow, MD, Uwe Platzbecker, Christoph Röllig, MD MSC, Richard F. Schlenk, MD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 2693.

https://doi.org/10.1182/blood-2019-125317

Published: 2019

Journal Articles

FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens

Yuichi Ishikawa, MD PhD, Koichi Saito, PhD, Naomi Kawashima, MD PhD, Michie Morimoto, Hidetoshi Murao, PhD, Daisuke Terada, Takeshi Yamaura, Shinji Hagiwara, PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 2672.

https://doi.org/10.1182/blood-2019-124632

Published: 2019

Journal Articles

Acceleration of AML Progression By Cigarette Smoke Exposure or Condensate Exposure and Associated DNA Methylation Alterations

Mary Figueroa, BS, Mansour Alfayez, MD, Yue Lu, PhD, Marcos Estecio, PhD, Seyed Javad Moghaddam, MD, Marina Y Konopleva, MD PhD, Elias Jabbour, MD, Courtney D. DiNardo, MDMSc, Joya Chandra, PhD

Blood (2019) 134 (Supplement_1): 2554.

https://doi.org/10.1182/blood-2019-127216

Published: 2019

Journal Articles

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Virginia Campos Silvestrini, BSc, MSc, Eduardo M Rego, MD PhD, Vitor Marcel Faca, PhD, João Agostinho Machado-Neto, PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 2689.

https://doi.org/10.1182/blood-2019-132129

Published: 2019

Journal Articles

Comparison of RNA-Based Versus DNA-Based Quantitative KIT D816V Mutation Analysis Reveals Significant Disparity in Patients with Advanced Systemic Mastocytosis

Mohamad Jawhar, Nicole Naumann, Johannes Lübke, Juliana Schwaab, Oliver Hofmann, Thomas Kielsgaard Kristensen, Karl Sotlar, Verena Haselmann, Sven Schneider, Georgia Metzgeroth, Henning D. Popp, Alice Fabarius, PhD, Peter Bugert, Wolf-Karsten Hofmann, MD PhD, Andreas Reiter

Blood (2019) 134 (Supplement_1): 2955.

https://doi.org/10.1182/blood-2019-128811

Published: 2019

Journal Articles

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Clare Oni, MD, Mufaddal Moonim, MD, Joana Desterro, MD, Clive Grattan, MD, Natalia Curto-Garcia, MD, Claire Woodley, Monika Ciesielska, Deimante Drasutyte, Yvonne Francis, Jennifer O'Sullivan, MD, Thompson Olaoni, Anna Green, MD, Miki Yurina, MD, Mark Ong, MD, Nick C.P. Cross, Professor, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia

Blood (2019) 134 (Supplement_1): 2960.

https://doi.org/10.1182/blood-2019-130477

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Annette E. Hay, Sarit Assouline, MD, Roland B. Walter, MD PhD MS, Richard F. Little, MD MPH, Anna Moseley, M.S., Sperling M Gail, MPH, CHES, Annie Im, MD, James M. Foran, MD, Jerald P. Radich, MD, Min Fang, MD PhD, Megan Othus, PhD, Harry P. Erba, MD PhD, Laura C. Michaelis, MD

Blood (2019) 134 (Supplement_1): 3905.

https://doi.org/10.1182/blood-2019-124320

Published: 2019

Journal Articles

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Alexander E. Perl, MD, Naval G. Daver, MD, Keith W. Pratz, MD, Joseph Maly, MD, Wan-Jen Hong, MD, Erkut Bahceci, Bo Tong, PhD, Tian Tian, PhD, Kimberley Dilley, MD MPH

Blood (2019) 134 (Supplement_1): 3910.

https://doi.org/10.1182/blood-2019-127416

Published: 2019

NARROW

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

How I treat acute myeloid leukemia in the era of new drugs

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Liposomal Daunorubicin/Cytarabine As a Bridge to Donor Lymphocyte Infusion or Allogeneic Stem Cell Transplantation for High-Risk Acute Myelogenous Leukemia

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens

Acceleration of AML Progression By Cigarette Smoke Exposure or Condensate Exposure and Associated DNA Methylation Alterations

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

Comparison of RNA-Based Versus DNA-Based Quantitative KIT D816V Mutation Analysis Reveals Significant Disparity in Patients with Advanced Systemic Mastocytosis

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only